Vertex Pharmaceuticals (VRTX) Total Liabilities (2009 - 2026)

Vertex Pharmaceuticals' Total Liabilities history runs 18 years deep, the most recent figure standing at $7.1 billion for Q1 2026.

• In Q1 2026, Total Liabilities rose 11.56% year-over-year to $7.1 billion; the TTM figure through Mar 2026 stood at $7.1 billion (up 11.56% YoY), while the FY2025 annual figure was $7.0 billion, up 13.94% from the prior year.
• Total Liabilities was $7.1 billion for Q1 2026 at Vertex Pharmaceuticals, up from $7.0 billion in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $7.5 billion in Q3 2025 to a low of $3.3 billion in Q1 2022.
• Historically, Total Liabilities has averaged $5.5 billion across 5 years, with a median of $5.4 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities gained 6.84% in 2022, then surged 41.79% in 2023.
• A 5-year view of Total Liabilities shows it stood at $4.2 billion in 2022, then gained by 21.51% to $5.1 billion in 2023, then advanced by 18.91% to $6.1 billion in 2024, then advanced by 13.94% to $7.0 billion in 2025, then increased by 2.08% to $7.1 billion in 2026.
• The last three Total Liabilities figures came in at $7.1 billion (Q1 2026), $7.0 billion (Q4 2025), and $7.5 billion (Q3 2025), per Business Quant data.